ERBB2 and neoplasm: Trastuzumab showed substantial anti-tumor efficacy in both preclinical and clinical trials [3,4], and introduction of trastuzumab for the treatment of HER2-positive breast cancer can be considered a milestone in medical oncology [4,5].